

---

May 20<sup>th</sup>, 2022

Zedira publication

## Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease

Authors: Christian Büchold, Martin Hils, Uwe Gerlach, Johannes Weber, Christiane Pelzer, Andreas Heil, Daniel Aeschlimann, and Ralf Pasternack

This article is published in *Cells*' Special Issue

**Function of Transglutaminases in Adhesion Dynamics, Differentiation, and Cell Survival**

The Open Access article is available for download:

[Cells | Free Full-Text | Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease \(mdpi.com\)](#)

---

Please notice that Zedira offers the full range of products for transglutaminase and celiac disease research. For detailed information concerning our products please refer to our web site: [www.zedira.com](http://www.zedira.com)

We are continuously enlarging our product portfolio to fulfil researcher's requirements in the field of transglutaminase R&D. Should you have any questions or queries about our products, please do not hesitate to contact us: [contact@zedira.com](mailto:contact@zedira.com)

---

This communication is published by:

**Zedira GmbH**

Roesslerstr. 83  
64293 Darmstadt  
Germany

Phone: +49 6151 66628-0

Fax: +49 6151 66628-19

Web: [www.zedira.com](http://www.zedira.com)

E-mail: [contact@zedira.com](mailto:contact@zedira.com)

© 2022, Zedira GmbH